Statistically significant results on primary endpoint of long-term study analyses Following FDA pre-NDA feedback, submission on track for December 2024 WARREN, N.J. , Oct. 8, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) provided today several positive updates on the vatiquinone Friedreich ataxia (FA) program. The pre-specified endpoint for two different FA long-term extension studies was met, with highly... Read More